Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.51 |
| ▸ | GPR39 | O43194 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17748962 | 0.99 | HRH4 (0.50) | HRH4GPR39NPC1TSHRRECQL | |
| SCHEMBL360521 | 0.80 | KDM4E (0.54) | HRH4 | |
| SCHEMBL28381103 | 0.79 | CKS1B (0.56) | SMO | |
| Hydrochloric Acid SCHEMBL27866106 | 0.79 | KDM4E (0.52) | HRH4 | |
| SCHEMBL19658510 | 0.76 | OPRD1 (0.47) | HRH4GPR39NPC1TSHRRECQL | |
| SCHEMBL803812 | 0.76 | HRH4 (0.56) | HRH4 | |
| SCHEMBL27557095 | 0.76 | HTR7 (0.59) | HRH4GPR39SMOROCK2ROCK1 | |
| SCHEMBL20813432 | 0.75 | ENPP1 (0.51) | GPR39NPC1TSHRRECQLRAB9A | |
| SCHEMBL17753925 | 0.75 | HRH4 (0.55) | HRH4 | |
| Hydrochloric Acid SCHEMBL785338 | 0.75 | HRH4 (0.55) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | HRH4 241/4885GPR39 2990/4885NPC1 1229/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | HRH4 241/4885GPR39 2990/4885NPC1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.